Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions

A Abaasa, Y Mayanja, G Asiki, MA Price, PE Fast… - Scientific reports, 2021 - nature.com
The design of HIV prevention trials in the context of effective HIV preventive methods is a
challenge. Alternate designs, including using non-randomised 'observational control arms' …

[HTML][HTML] Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda

A Abaasa, S Nash, Y Mayanja, M Price, PE Fast… - Vaccine, 2019 - Elsevier
Background Fisherfolks (FF) and female sex workers (FSW) in Uganda could be suitable key
populations for HIV vaccine efficacy trials because of the high HIV incidence and good …

Feasibility of conducting HIV prevention trials among key populations in Nairobi, Kenya

EM Mutisya, V Muturi-Kioi, A Abaasa, D Nyasani… - BMC public health, 2022 - Springer
Objective To assess the feasibility of conducting HIV prevention trials among key
populations in Nairobi, Kenya. Background HIV prevention trials require the inclusion of …

Comparison of retention in observational cohorts and nested simulated HIV vaccine efficacy trials in the key populations in Uganda

A Abaasa, J Todd, S Nash, Y Mayanja… - BMC medical research …, 2020 - Springer
Background Outcomes in observational studies may not best estimate those expected in the
HIV vaccine efficacy trials. We compared retention in Simulated HIV Vaccine Efficacy Trials …

[HTML][HTML] Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: implications for sample …

A Abaasa, G Asiki, MA Price, E Ruzagira, F Kibengo… - Vaccine, 2016 - Elsevier
Background Clinical trial participants may differ from the source population due to the
demands of trial participation and self-selection, inadvertent selection of a lower-risk group …

Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important

F Laher, T Salami, S Hornschuh, LM Makhale… - BMC Public Health, 2020 - Springer
Background Despite multiple available HIV prevention methods, the HIV epidemic continues
to affect South Africa the most. We sought to understand willingness to use actual and …

Ongoing vaccine and monoclonal antibody HIV prevention efficacy trials and considerations for sequel efficacy trial designs

PB Gilbert - Statistical communications in infectious diseases, 2019 - degruyter.com
Four randomized placebo-controlled efficacy trials of a candidate vaccine or passively
infused monoclonal antibody for prevention of HIV-1 infection are underway (HVTN 702 in …

Use of varied screening risk criteria and HIV incidence in phase 1 and 2 HIV vaccine trials in South Africa

F Laher, K Otwombe, O Mokwena, LG Bekker… - AIDS and Behavior, 2023 - Springer
Many early phase HIV prevention studies define HIV risk-related eligibility criteria. We
conducted a retrospective review of HIV Vaccine Trials Network (HVTN) Phase 1 and 2 HIV …

Designing HIV vaccine efficacy trials in the context of highly effective non-vaccine prevention modalities

H Janes, Y Zhu, ER Brown - Statistics in biosciences, 2020 - Springer
The evolving HIV prevention landscape poses challenges to the statistical design of future
trials of candidate HIV vaccines. Study designs must address the anticipated reduction in …

HIV prevention responsibilities in HIV vaccine trials: complexities facing South African researchers

Z Essack, C Slack, J Koen, G Gray - South African Medical Journal, 2010 - ajol.info
ORIGINAL ARTICLES HIV prevention responsibilities in HIV vaccine trials: Complexities facing
South African researchers Page 1 ORIGINAL ARTICLES 45 HIV prevention responsibilities in …